ISLET AMYLOID POLYPEPTIDE IN PATIENTS WITH PANCREATIC-CANCER AND DIABETES
ISLET AMYLOID POLYPEPTIDE IN PATIENTS WITH PANCREATIC-CANCER AND DIABETES
复制标题
DOI：
10.1056/nejm199402033300503
复制
发表时间：
1994-02-03
影响因子：
158.5
通讯作者：
ADRIAN, TE
中科院分区：
文献类型：
--
作者：
PERMERT, J;LARSSON, J;ADRIAN, TE
背景胰腺癌患者中发生的糖尿病的特征在于显著的胰岛素抵抗，其在肿瘤切除后下降。胰岛淀粉样多肽（IAPP）是一种由胰腺β细胞分泌的激素因子，可降低体内胰岛素敏感性和体外糖原合成。在这项研究中，我们研究了胰腺癌患者的IAPP和糖尿病之间的关系。我们检测了30例胰腺癌患者、46例其他癌症患者、23例糖尿病患者和25例正常人血浆中的IAPP。研究了胰腺癌、癌旁胰腺组织和正常胰腺组织中IAPP的免疫反应性和IAPP信使RNA。胰腺癌患者血浆IAPP浓度高于正常人（平均值[+/-SD]，22.3+/-13.6 pmol/L vs. 8.0+/-5.0 pmol/L; P
Background. The diabetes mellitus that occurs in patients with pancreatic cancer is characterized by marked insulin resistance that declines after tumor resection. Islet amyloid polypeptide (IAPP), a hormonal factor secreted from the pancreatic beta cells, reduces insulin sensitivity in vivo and glycogen synthesis in vitro. In this study, we examined the relation between IAPP and diabetes in patients with pancreatic cancer.Methods. We measured IAPP in plasma from 30 patients with pancreatic cancer, 46 patients with other cancers, 23 patients with diabetes, and 25 normal subjects. IAPP immunoreactivity and IAPP messenger RNA were studied in pancreatic cancers, pancreatic tissue adjacent to cancers, and normal pancreatic tissue.Results. Plasma IAPP concentrations were elevated in the patients with pancreatic cancer as compared with the normal subjects (mean [+/-SD], 22.3+/-13.6 vs. 8.0+/-5.0 pmol per liter; P